



## HBIO Settles Name Dispute with Harvard University

BIOWIRE2K

HOLLISTON, Mass.--(BUSINESS WIRE)--Jan. 14, 2003--Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that it has settled its dispute with Harvard University by way of a license agreement with Harvard University that enables HBIO to continue using the names Harvard Apparatus, Harvard Bioscience and various Harvard related product names. Harvard Bioscience will continue to be used as the company's name and Harvard Apparatus and various Harvard related product names will continue to be used as brand names on products and catalogs. The names will be used subject to various stylistic restrictions which primarily include avoiding the use of the color crimson and fonts that are similar to those regularly used by Harvard University.

About Harvard Bioscience, Inc.

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments, used to accelerate drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its direct sales force, its 1,000 page catalog (and various other specialty catalogs), and through its distributors, including Amersham Biosciences and PerkinElmer. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Austria and Belgium with sales facilities in Japan, France and Canada. For more information please visit [www.harvardbioscience.com](http://www.harvardbioscience.com)

The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements or inferences about the significance and effects of the licensing of trademarks on the Company's competitive position or the perception of the Company's products, or on the Company's financial condition, results of operations or stock price. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.

### CONTACT:

Harvard Bioscience, Inc.  
Investor information  
David Green, 508/893-8999  
[dgreen@harvardbioscience.com](mailto:dgreen@harvardbioscience.com)

### Disclaimer:

The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrences or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience's web site. For Harvard Bioscience's most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at <http://www.sec.gov>.